• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

古塞库单抗治疗合并克罗恩病的化脓性汗腺炎患者：有效性和安全性的病例报告及系统文献综述

Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn's disease: Report and systematic literature review of effectiveness and safety.

作者信息

Jørgensen Astrid-Helene Ravn, Holm Jesper Grønlund, Thomsen Simon Francis

机构信息

Department of Dermato-Venereology & Wound Healing Centre Bispebjerg Hospital Copenhagen Denmark.

Department of Biomedical Sciences University of Copenhagen Copenhagen Denmark.

出版信息

Clin Case Rep. 2020 Sep 10;8(12):2874-2877. doi: 10.1002/ccr3.3090. eCollection 2020 Dec.

DOI:10.1002/ccr3.3090
PMID:33363841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7752321/
Abstract

Guselkumab appears to be safe and effective in the treatment of patients with HS, who do not respond to adalimumab and other systemic therapies. Guselkumab can be used in patients with comorbid Crohn's disease.

摘要

古塞库单抗在治疗对阿达木单抗和其他全身疗法无反应的化脓性汗腺炎患者中似乎是安全有效的。古塞库单抗可用于合并克罗恩病的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed6f/7752321/19f29b5696ce/CCR3-8-2874-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed6f/7752321/cead6ad66f60/CCR3-8-2874-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed6f/7752321/19f29b5696ce/CCR3-8-2874-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed6f/7752321/cead6ad66f60/CCR3-8-2874-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed6f/7752321/19f29b5696ce/CCR3-8-2874-g002.jpg

相似文献

1
Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn's disease: Report and systematic literature review of effectiveness and safety.古塞库单抗治疗合并克罗恩病的化脓性汗腺炎患者：有效性和安全性的病例报告及系统文献综述
Clin Case Rep. 2020 Sep 10;8(12):2874-2877. doi: 10.1002/ccr3.3090. eCollection 2020 Dec.
2
The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.临床实践条件下古塞奇尤单抗治疗化脓性汗腺炎患者的疗效：一项西班牙多中心回顾性研究。
3
The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.临床实践条件下古塞奇尤单抗治疗化脓性汗腺炎患者的疗效：一项西班牙多中心回顾性研究。
Actas Dermosifiliogr. 2023 Oct;114(9):755-762. doi: 10.1016/j.ad.2023.06.013. Epub 2023 Jun 16.
4
Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.古塞库单抗治疗化脓性汗腺炎、银屑病和克罗恩病。
J Dermatolog Treat. 2021 Mar;32(2):261-263. doi: 10.1080/09546634.2019.1654067. Epub 2019 Aug 25.
5
Features of Patients With Crohn's Disease and Hidradenitis Suppurativa.克罗恩病与化脓性汗腺炎患者的特征。
Clin Gastroenterol Hepatol. 2016 Jan;14(1):71-9. doi: 10.1016/j.cgh.2015.04.180. Epub 2015 May 5.
6
Hidradenitis suppurativa in Crohn's disease during adalimumab therapy: a paradox?阿达木单抗治疗克罗恩病期间出现化脓性汗腺炎：自相矛盾？
Acta Dermatovenerol Alp Pannonica Adriat. 2017 Mar;26(1):21-23. doi: 10.15570/actaapa.2017.6.
7
Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: A retrospective bicentric experience.古塞库单抗治疗中度至重度化脓性汗腺炎的有效性及用药剂量：一项双中心回顾性研究经验
Dermatol Ther. 2022 Jul;35(7):e15558. doi: 10.1111/dth.15558. Epub 2022 May 13.
8
Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn's Disease?化脓性汗腺炎作为克罗恩病患者使用阿达木单抗的一种矛盾的副作用？
Clin Exp Gastroenterol. 2020 Aug 19;13:293-298. doi: 10.2147/CEG.S263685. eCollection 2020.
9
Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study.古塞单抗治疗化脓性汗腺炎的 II 期、开放标签、作用机制研究。
Br J Dermatol. 2023 Apr 20;188(5):601-609. doi: 10.1093/bjd/ljad010.
10
Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.皮肤科和性病科在莫斯塔尔临床医院用阿达木单抗治疗两例化脓性汗腺炎。
Acta Dermatovenerol Croat. 2021 Jul;29(2):108-110.

引用本文的文献

1
Guselkumab - In Psoriasis and Beyond.古塞库单抗——用于银屑病及其他病症
Dermatol Pract Concept. 2024 Jul 1;14(3):e2024181. doi: 10.5826/dpc.1403a181.
2
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report.古塞库单抗治疗青少年化脓性汗腺炎的长期疗效：一例报告
Clin Cosmet Investig Dermatol. 2024 Feb 29;17:483-487. doi: 10.2147/CCID.S456817. eCollection 2024.
3
Hidradenitis Suppurativa in Children and Adolescents: An Update on Pharmacologic Treatment Options.儿童和青少年化脓性汗腺炎：药物治疗选择的最新进展。

本文引用的文献

1
The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review.每4周使用100毫克古塞库单抗治疗化脓性汗腺炎患者及文献综述
Dermatol Ther. 2020 May;33(3):e13456. doi: 10.1111/dth.13456. Epub 2020 May 3.
2
Successful use of guselkumab in the treatment of severe hidradenitis suppurativa.古塞库单抗成功用于治疗重度化脓性汗腺炎。
Clin Exp Dermatol. 2020 Jul;45(5):618-619. doi: 10.1111/ced.14199. Epub 2020 Mar 30.
3
Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
Paediatr Drugs. 2023 Nov;25(6):659-676. doi: 10.1007/s40272-023-00595-6. Epub 2023 Oct 2.
4
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data.古塞库单抗、司库奇尤单抗和替拉珠单抗治疗化脓性汗腺炎：现有试验及真实世界数据综述
Clin Cosmet Investig Dermatol. 2023 Sep 18;16:2525-2536. doi: 10.2147/CCID.S418748. eCollection 2023.
5
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.化脓性汗腺炎的新兴治疗方法及临床试验概况 第一部分：局部和全身药物治疗
Dermatol Ther (Heidelb). 2023 Aug;13(8):1661-1697. doi: 10.1007/s13555-023-00956-6. Epub 2023 Jul 4.
6
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.深入了解化脓性汗腺炎的分子发病机制和免疫调节治疗。
Int J Mol Sci. 2023 May 8;24(9):8428. doi: 10.3390/ijms24098428.
7
Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.免疫调节药物治疗化脓性汗腺炎：可能性与局限性。
Int J Mol Sci. 2022 Aug 26;23(17):9716. doi: 10.3390/ijms23179716.
8
Successful treatment of hidradenitis suppurativa and Crohn's disease with combined guselkumab and apremilast.古塞库单抗和阿普司特联合治疗化脓性汗腺炎和克罗恩病取得成功。
Dermatol Ther. 2022 Oct;35(10):e15743. doi: 10.1111/dth.15743. Epub 2022 Aug 12.
9
New and Emerging Targeted Therapies for Hidradenitis Suppurativa.化脓性汗腺炎的新型及新兴靶向治疗方法
Int J Mol Sci. 2022 Mar 29;23(7):3753. doi: 10.3390/ijms23073753.
10
New perspectives on the treatment of hidradenitis suppurativa.化脓性汗腺炎治疗的新视角。
Ther Adv Chronic Dis. 2021 Nov 23;12:20406223211055920. doi: 10.1177/20406223211055920. eCollection 2021.
古塞库单抗治疗化脓性汗腺炎、银屑病和克罗恩病。
J Dermatolog Treat. 2021 Mar;32(2):261-263. doi: 10.1080/09546634.2019.1654067. Epub 2019 Aug 25.
4
Pharmacological development in hidradenitis suppurativa.化脓性汗腺炎的药物研发。
Curr Opin Pharmacol. 2019 Jun;46:65-72. doi: 10.1016/j.coph.2019.04.006. Epub 2019 May 7.
5
Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review.古塞库单抗治疗化脓性汗腺炎：一项回顾性病历审查。
J Am Acad Dermatol. 2019 Jul;81(1):265-267. doi: 10.1016/j.jaad.2018.12.017. Epub 2018 Dec 15.
6
Guselkumab in the treatment of severe hidradenitis suppurativa.古塞库单抗治疗重度化脓性汗腺炎
J Eur Acad Dermatol Venereol. 2019 Mar;33(3):e140-e141. doi: 10.1111/jdv.15368. Epub 2019 Feb 18.
7
The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis.美国化脓性汗腺炎的共病负担：一项索赔数据分析
Dermatol Ther (Heidelb). 2018 Dec;8(4):557-569. doi: 10.1007/s13555-018-0264-z. Epub 2018 Oct 10.
8
Guselkumab for the treatment of psoriasis.古塞库单抗治疗银屑病。
Expert Opin Biol Ther. 2018 Apr;18(4):459-468. doi: 10.1080/14712598.2018.1445223. Epub 2018 Mar 3.
9
The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa.血清促炎细胞因子、C 反应蛋白和红细胞沉降率升高对化脓性汗腺炎患者的临床意义。
Mediators Inflamm. 2017;2017:2450401. doi: 10.1155/2017/2450401. Epub 2017 Jul 10.
10
Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview.用于慢性免疫介导疾病的肿瘤坏死因子-α阻断剂及其他生物制剂下的反常反应：分析性与综合性概述
RMD Open. 2016 Jul 15;2(2):e000239. doi: 10.1136/rmdopen-2015-000239. eCollection 2016.